FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year

By Yahoo! Finance | Oct 17, 2024 at 11:40 AM EST

The FDA approved AbbVie's Vyalev for advanced Parkinson's disease, providing a 24-hour subcutaneous infusion of levodopa therapy. The treatment showed superior results in improving motor fluctuations compared to oral medication. Medicare coverage is expected in late 2025.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.